国际产前诊断学会2024年辩论3:细胞遗传学是恐龙,应被分子技术取代
本文总结第28届国际产前诊断与胎儿治疗会议上关于产前遗传检测的辩论,探讨胎儿外显子或基因组测序等分子技术是否应取代G显带染色体和FISH等细胞遗传学技术及靶向基因面板筛查作为所有产前诊断的一线检测,双方专家讨论了优缺点,但缺乏共识。
要点
- G显带染色体和FISH分析长期是产前遗传检测的金标准。
- 胎儿外显子或基因组测序等分子技术日益普及,尤其用于结构异常胎儿。
- 尚无共识是否应以分子技术取代细胞遗传学作为所有产前诊断的一线检测。
核心结论
- 目前缺乏共识是否胎儿外显子或基因组测序应取代细胞遗传学技术和靶向基因面板筛查作为所有产前诊断的一线检测。
研究设计与样本
- 本文为第28届国际产前诊断与胎儿治疗会议上专家辩论的总结。
主要发现
- 新兴研究正在确立分子技术具有更高的诊断产出。
- 两位专家辩论者讨论了分子技术和细胞遗传学技术的优点和缺点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytogenetic technologies such as G-banding chromosome and FISH analyses have long been the gold standard diagnostic test in prenatal genetic testing. However, unbiased next-generation sequencing technologies such as fetal exome or genome sequencing (ES/GS) are becoming widely accessible and increasingly utilized, particularly for fetuses with structural anomalies. Emerging studies are now establishing increased diagnostic yields from molecular technologies, but there remains a lack of consensus as to whether ES/GS should replace cytogenetic technologies and targeted genepanel screening as first-line tests for all prenatal diagnoses. This report is a summary of the debate on this topic presented at the 28th International Conference on Prenatal Diagnosis and Fetal Therapy. Both expert debaters discussed the advantages and disadvantages.
引用
- Akkari YMN, Talkowski ME, Breman AM, et al. International Society for Prenatal Diagnosis 2024 Debate 3-Cytogenetics Is a Dinosaur and Should Be Replaced by Molecular Technologies. Prenat Diagn. 2025. PMID: 40751292. doi:10.1002/pd.6847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。